Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01517035 · ClinicalTrials.gov registry record · Phase 1

Improving Blood Stem Cell Collection and Transplant Procedures

A Phase 1 study of Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
1
Study location

NCT01517035: Completed Phase 1 study of Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

NCT01517035 is a Phase 1 study of Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 43 participants, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01517035, a Phase 1 study of Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

Background: \- People who have some kinds of cancer can benefit from donated bone marrow stem cells. These stem cells help produce healthy bone marrow and slow or stop the spread of abnormal cells. However, stem cells transplants do not always work. Also, they may have serious side effects that can cause illness or death. The Bone Marrow Stem Cell Transplant Program is studying methods to make stem cell transplant procedures safer and more effective. Objectives: \- To test a new procedure that may improve the success and decrease the side effects of stem cell transplants. Eligibility: * Individuals 10 to 75 years of age who have a life-threatening illness that may require a stem cell transplant. * Healthy siblings who are able to provide stem cells for transplant. Design: * Participants will be screened with a medical history, physical exam, and blood and urine tests. * Donor procedures: * Stem cell donors will start by having apheresis to donate white blood cells. * Donors will receive filgrastim shots for 5 days to help move stem cells into the blood for collection. * Donors will have another round of apheresis to donate the stem cells for transplant. * Recipient procedures: * Before the transplant, recipients will have radiation twice a day for 3 days and chemotherapy for 7 days. * After the radiation and chemotherapy, recipients will receive the stem cells provided by the donor. * After the transplant, recipients will receive the white blood cells provided by the donor. * Recipients will be monitored closely for 4 months to study the success of the transplant. They will have more followup visits at least yearly thereafter. * Recipients will have a research apheresis prior to transplant and at 3 months.

Interventions

  • PROCEDURE Stem Cell Transplantation

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2012-01-13
Est. Completion 2017-03-29
Phase Phase 1

What the finished NCT01517035 record still lists

NCT01517035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 382-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (89% lower).

The record links to 5 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Stem Cell Transplantation is the first listed.

NCT01517035 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01517035 about?

NCT01517035 is a clinical study titled "Improving Blood Stem Cell Collection and Transplant Procedures". Background: \- People who have some kinds of cancer can benefit from donated bone marrow stem cells. These stem cells help produce healthy bone marrow and slow or stop the spread of abnormal cells. However, stem cells transplants do not always work. Also, they may have serious side effects that can...

What is the current status of trial NCT01517035?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2012-01-13. Estimated completion is 2017-03-29.

What conditions does trial NCT01517035 study?

This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome (MDS), CLL (Chronic Lymphocytic Leukemia), CML (Chronic Myelogenous Leukemia).

What interventions are being tested in trial NCT01517035?

The interventions under investigation include: Stem Cell Transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT01517035?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01517035 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01517035's enrollment target sits among peer trials

43 80th of 131 higher than 52 of 131 other Acute Lymphoblastic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01517035, the US trial registry maintained by the National Library of Medicine. NCT01517035 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.